Uses of Prasugen: - Prevention of heart attack and stroke - Heart attack Acute coronary syndromes, thrombotic cardiovascular (CV) events, stent thrombosis, unstable angina (UA), non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI), Stroke Active pathological bleeding such as peptic ulcer or intracranial hamorrhage. Patient with a history of prior transient ischemic attack or stroke

How to use Prasugrel: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Prasugrel may be taken with or without food, but it is better to take it at a fixed time. Administration: May be taken with or without food. Adult Dose: Oral Acute coronary syndrome Adult: 60 mg as loading dose, followed by 10 mg once daily for up to 12 mth, given in combination w/ aspirin. Elderly: >75 yr Maintenance: 5 mg once daily. Patient w/ low body wt (<60 kg): 5 mg once daily as maintenance dose. Hepatic impairment: Severe (Child-Pugh class C): Contraindicated. Renal Dose: Renal impairment Dose adjustment not necessary

Increased risk of bleeding w/ oral anticoagulants (e.g. warfain), clopidogrel, NSAIDs and fibrinolytics.

Active pathological bleeding such as peptic ulcer or intracranial hamorrhage. Patient with a history of prior transient ischemic attack or stroke

Common - Bleeding 1-10% Bleeding,Anemia,Atrial fibrillation,Back pain,Bradycardia,Dizziness,Dyspnea,Headache,Hypertension,Nausea <1% Thrombotic thrombocytopenic purpura,Abnormal hepatic function,Angioedema,Hematoma,Hemolysis,Hemorrhage,Abnormal liver function

Precaution: Patient w/ propensity to bleed, low body wt (<60 kg). Patient who will undergo CABG and other surgical procedure; coronary angiography in UA/NSTEMI patients. Elderly (>75 yr). Pregnancy and lactation. Monitoring Parameters Monitor Hb and haematocrit periodically; may consider platelet function testing.

Prasugrel is a prodrug that inhibits platelet activation and aggregation. The active metabolite irreversibly blocks the P2Y12 component of adenosine diphosphate (ADP) receptors on the platelet, which prevents activation of the GPIIb/IIIa receptor complex, thereby reducing platelet activation and aggregation.